Table 2 Changes in proportions of subsets and surface markers of T cells during tocilizumab treatment

CD4⁺ T cells/lymphocytes

53.6 (47.3 to 59.4)

53.4 (47.3 to 58.4)

55.3 (49.5 to 60.5)

Naïve CD4⁺ T cells/CD4⁺ T cells

61.8 (57.7 to 69.3)

59.1 (53.7 to 62.2)

59.1 (51.8 to 61.8)

Memory CD4⁺ T cells/CD4⁺ T cells

30.7 (30.7 to 42.3)

40.9 (37.8 to 46.3)

40.9 (38.2 to 48.2)

HLA-DR⁺CD4⁺ T cells/CD4⁺ T cells

3.2 (2.7 to 4.1)

3.1 (2.6 to 3.9)

2.6 (2 to 3.1)

CD38⁺CD4⁺ T cells/CD4⁺ T cells

32.4 (26.3 to 38.5)

32.4 (28.4 to 39.4)

32.6 (29.3 to 40.1)

CD69⁺CD4⁺ T cells/CD4⁺ T cells

0.1 (0 to 0.1)

0.1 (0 to 0.2)

0.1 (0.1 to 0.3)

CD8⁺ T cells/lymphocytes

32.4 (28.4 to 38.1)

30.8 (26.9 to 37.1)

29.1 (26.4 to 33.1)

Naïve CD8⁺ T cells/CD8⁺ T cells

60.8 (57.7 to 64.3)

62.1 (59.5 to 67.5)

62.7 (59.5 to 67.5)

Memory CD8⁺ T cells/CD8⁺ T cells

39.2 (35.7 to 42.3)

37.9 (33.9 to 41.5)

37.3 (32.5 to 40.5)

HLA-DR⁺CD8⁺ T cells/CD8⁺ T cells

16.4 (13.4 to 19.4)

18.3 (14.3 to 19.4)

19.4 (17.3 to 21.4)

CD38⁺CD8⁺ T cells/CD8⁺ T cells

25.2 (15.9 to 36.7)

26.1 (19.3 to 31.4)

24.5 (19.4 to 30)

CD69⁺CD8⁺ T cells/CD8⁺ T cells

1.3 (0.5 to 2.1)

1.3 (0.9 to 2.1)

0.9 (0.3 to 1.3)

T_reg/CD4⁺ T cells

3.6 (2.2 to 4.3)

4.2 (2.6 to 5.2)

5.6 (4.5 to 7.1)

Naïve T_reg/T_reg cells

52.8 (44.0 to 59.0)

47.7 (42.6 to 54.9)

49.6 (46.5 to 55.7)

Memory T_reg/T_reg cells

47.2 (41 to 56.1)

52.3 (45.1 to 57.4)

50.4 (44.3 to 53.5)

HLA-DR⁺ T_reg/ T_reg cells

14 (11.7 to 17.7)

16.8 (14.3 to 20.3)

18.4 (15.4 to 19.4)

T_H1/CD4⁺ T cells

19 (14.8 to 20.8)

17.4 (15.3 to 19.3)

20.7 (15.9 to 22.9)

HLA-DR⁺ T_H1/T_H1 cells

4.5 (3.4 to 5.7)

4.5 (3.4 to 5.7)

3.5 (2.2 to 5.6)

T_H2/CD4⁺ T cells

46.8 (37.7 to 54.3)

51.8 (42.5 to 58.7)

43.3 (34.6 to 49.1)

HLA-DR⁺ T_H2/T_H2 cells

2.0 (1.2 to 3.1)

2.3 (1.9 to 2.9)

2.2 (1.8 to 2.9)

T_H17/CD4⁺ T cells

2.0 (0.78 to 3.2)

2.0 (1.4 to 3.2)

2.0 (1.5 to 3.6)

HLA-DR⁺ T_H17/T_H17 cells

4.0 (3.4 to 4.4)

3.6 (3.1 to 4.1)

3.9 (3.3 to 4.2)